242 related articles for article (PubMed ID: 24954688)
21. Simultaneous quantification of the abundance of several cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase enzymes in human liver microsomes using multiplexed targeted proteomics.
Achour B; Russell MR; Barber J; Rostami-Hodjegan A
Drug Metab Dispos; 2014 Apr; 42(4):500-10. PubMed ID: 24408517
[TBL] [Abstract][Full Text] [Related]
22. In Vitro Inhibitory Effects of Synthetic Cannabinoid EAM-2201 on Cytochrome P450 and UDP-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes.
Kong TY; Kwon SS; Cheong JC; Kim HS; Kim JY; Lee HS
Molecules; 2018 Apr; 23(4):. PubMed ID: 29659506
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of cytochrome P450 enzymes by saturated and unsaturated fatty acids in human liver microsomes, characterization of enzyme kinetics in the presence of bovine serum albumin (0.1 and 1.0% w/v) and in vitro - in vivo extrapolation of hepatic clearance.
Palacharla RC; Uthukam V; Manoharan A; Ponnamaneni RK; Padala NP; Boggavarapu RK; Bhyrapuneni G; Ajjala DR; Nirogi R
Eur J Pharm Sci; 2017 Apr; 101():80-89. PubMed ID: 28179134
[TBL] [Abstract][Full Text] [Related]
24. Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A9: application to the reaction phenotyping of acetaminophen glucuronidation.
Miners JO; Bowalgaha K; Elliot DJ; Baranczewski P; Knights KM
Drug Metab Dispos; 2011 Apr; 39(4):644-52. PubMed ID: 21245288
[TBL] [Abstract][Full Text] [Related]
25. Assessment of the inhibition risk of paris saponins, bioactive compounds from Paris polyphylla, on CYP and UGT enzymes via cocktail inhibition assays.
Luo H; Xu Y; Sun D; Cheng Y; Sun Z; Gao J; Zhang Y; Wang X
Regul Toxicol Pharmacol; 2020 Jun; 113():104637. PubMed ID: 32145316
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of DA-9801, a new herbal drug for diabetic neuropathy, on metabolism-mediated interaction.
Ji HY; Liu KH; Kong TY; Jeong HU; Choi SZ; Son M; Cho YY; Lee HS
Arch Pharm Res; 2013 Jan; 36(1):1-5. PubMed ID: 23371804
[TBL] [Abstract][Full Text] [Related]
27. Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro-in vivo extrapolation of drug clearance.
Wattanachai N; Tassaneeyakul W; Rowland A; Elliot DJ; Bowalgaha K; Knights KM; Miners JO
Drug Metab Dispos; 2012 May; 40(5):982-9. PubMed ID: 22331994
[TBL] [Abstract][Full Text] [Related]
28. In vitro metabolism of jaceosidin and characterization of cytochrome P450 and UDP-glucuronosyltransferase enzymes in human liver microsomes.
Song WY; Ji HY; Baek NI; Jeong TS; Lee HS
Arch Pharm Res; 2010 Dec; 33(12):1985-96. PubMed ID: 21191764
[TBL] [Abstract][Full Text] [Related]
29. Traditional Herbal Formulas to as Treatments for Musculoskeletal Disorders: Their Inhibitory Effects on the Activities of Human Microsomal Cytochrome P450s and UDP-glucuronosyltransferases.
Jin SE; Seo CS; Shin HK; Ha H
Pharmacogn Mag; 2016; 12(48):241-252. PubMed ID: 27867264
[TBL] [Abstract][Full Text] [Related]
30. The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities.
Rowland A; Knights KM; Mackenzie PI; Miners JO
Drug Metab Dispos; 2008 Jun; 36(6):1056-62. PubMed ID: 18362158
[TBL] [Abstract][Full Text] [Related]
31. Metabolism-mediated drug interaction potential of HS-23, a new herbal drug for the treatment of sepsis in human hepatocytes and liver microsomes.
Jeong HU; Lee JY; Kwon SS; Kim JH; Kim YM; Hong SW; Yeon SH; Lee SM; Cho YY; Lee HS
Arch Pharm Res; 2015 Feb; 38(2):171-7. PubMed ID: 25052959
[TBL] [Abstract][Full Text] [Related]
32. Potential Determinants for Metabolic Fates and Inhibitory Effects of Isobavachalcone Involving in Human Cytochrome P450, UDP-Glucuronosyltransferase Enzymes, and Efflux Transporters.
Qin Z; Wang P; Duan S; Wan X; Xing H; Yang J; Zhang X; Yao Z; Yao X
J Pharm Sci; 2021 May; 110(5):2285-2294. PubMed ID: 33610566
[TBL] [Abstract][Full Text] [Related]
33. In vitro characterization of the metabolic pathways and cytochrome P450 inhibition and induction potential of BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor.
Hong H; Su H; Ma L; Yao M; Iyer RA; Humphreys WG; Christopher LJ
Drug Metab Dispos; 2011 Sep; 39(9):1658-67. PubMed ID: 21673131
[TBL] [Abstract][Full Text] [Related]
34. Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes.
Kilford PJ; Stringer R; Sohal B; Houston JB; Galetin A
Drug Metab Dispos; 2009 Jan; 37(1):82-9. PubMed ID: 18832476
[TBL] [Abstract][Full Text] [Related]
35. Effect of uremic serum and uremic toxins on drug metabolism in human microsomes.
Volpe DA; Tobin GA; Tavakkoli F; Dowling TC; Light PD; Parker RJ
Regul Toxicol Pharmacol; 2014 Mar; 68(2):297-303. PubMed ID: 24184159
[TBL] [Abstract][Full Text] [Related]
36. Coimmunoprecipitation of UDP-glucuronosyltransferase isoforms and cytochrome P450 3A4.
Fremont JJ; Wang RW; King CD
Mol Pharmacol; 2005 Jan; 67(1):260-2. PubMed ID: 15486048
[TBL] [Abstract][Full Text] [Related]
37. The different metabolism of morusin in various species and its potent inhibition against UDP-glucuronosyltransferase (UGT) and cytochrome p450 (CYP450) enzymes.
Shi X; Yang S; Zhang G; Song Y; Su D; Liu Y; Guo F; Shan L; Cai J
Xenobiotica; 2016; 46(5):467-76. PubMed ID: 26372370
[TBL] [Abstract][Full Text] [Related]
38. Glucuronidation of edaravone by human liver and kidney microsomes: biphasic kinetics and identification of UGT1A9 as the major UDP-glucuronosyltransferase isoform.
Ma L; Sun J; Peng Y; Zhang R; Shao F; Hu X; Zhu J; Wang X; Cheng X; Zhu Y; Wan P; Feng D; Wu H; Wang G
Drug Metab Dispos; 2012 Apr; 40(4):734-41. PubMed ID: 22238289
[TBL] [Abstract][Full Text] [Related]
39.
Zhang X; Feng P; Gao X; Wang B; Gou C; Bian R
Pharm Biol; 2020 Dec; 58(1):247-252. PubMed ID: 32223485
[No Abstract] [Full Text] [Related]
40. Development of a method to determine cytochrome P450 1A2, 2C9, 2D6 and 3A4 activity sheep hepatic microsomes.
McBride GM; Soo JY; Varcoe T; Morrison JL; Wiese MD
J Pharmacol Toxicol Methods; 2020; 106():106934. PubMed ID: 33080390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
